Your browser doesn't support javascript.
loading
Persistent serum protein signatures define an inflammatory subset of long COVID
Aarthi Talla; Suhas V Vasaikar; Gregory Szeto; Maria P Lemos; Julie L Czartoski; Hugh MacMillan; Zoe Moodie; Kristen W Cohen; Lamar B Fleming; Zachary Thomson; Lauren Okada; Lynne A Becker; Ernest M Coffey; Stephen C DeRosa; Evan W Newell; Peter J Skene; Xiaojun Li; Thomas F Bumol; M. Juliana McElrath; Troy R Torgerson.
Afiliação
  • Aarthi Talla; Allen Institute for Immunology; Seattle, USA
  • Suhas V Vasaikar; Allen Institute for Immunology; Seattle, USA
  • Gregory Szeto; Allen Institute for Immunology; Seattle, USA
  • Maria P Lemos; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Julie L Czartoski; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Hugh MacMillan; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Zoe Moodie; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Kristen W Cohen; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Lamar B Fleming; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Zachary Thomson; Allen Institute for Immunology; Seattle, USA
  • Lauren Okada; Allen Institute for Immunology; Seattle, USA
  • Lynne A Becker; Allen Institute for Immunology; Seattle, USA
  • Ernest M Coffey; Allen Institute for Immunology; Seattle, USA
  • Stephen C DeRosa; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Evan W Newell; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Peter J Skene; Allen Institute for Immunology; Seattle, USA
  • Xiaojun Li; Allen Institute for Immunology; Seattle, USA
  • Thomas F Bumol; Allen Institute for Immunology; Seattle, USA
  • M. Juliana McElrath; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA
  • Troy R Torgerson; Allen Institute for Immunology; Seattle, USA
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-491196
ABSTRACT
Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring diverse symptoms that can persist for months after acute SARS-CoV-2 infection. The etiologies are unknown but may include persistent inflammation, unresolved tissue damage, or delayed clearance of viral protein or RNA. Attempts to classify subsets of PASC by symptoms alone have been unsuccessful. To molecularly define PASC, we evaluated the serum proteome in longitudinal samples from 55 PASC individuals with symptoms lasting [≥]60 days after onset of acute infection and compared this to symptomatically recovered SARS-CoV-2 infected and uninfected individuals. We identified subsets of PASC with distinct signatures of persistent inflammation. Type II interferon signaling and canonical NF-{kappa}B signaling (particularly associated with TNF), were the most differentially enriched pathways. These findings help to resolve the heterogeneity of PASC, identify patients with molecular evidence of persistent inflammation, and highlight dominant pathways that may have diagnostic or therapeutic relevance. One Sentence SummarySerum proteome profiling identifies subsets of long COVID patients with evidence of persistent inflammation including key immune signaling pathways that may be amenable to therapeutic intervention.
Licença
cc_no
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Etiology_studies / Experimental_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Etiology_studies / Experimental_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint